Analytical Data
-
Gene name
CPLX4
- Application
-
Alternative Names
CPX IV
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q80WM3
-
Expression Region
Asn15~Met160
-
Molecular Weight
47kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CPLX4, a member of the complexin family of proteins, plays a crucial role in the regulation of synaptic transmission and neurotransmitter release. Research on CPLX4 is driven by its potential implications in various neuropsychiatric disorders and neurological diseases, including autism spectrum disorders and schizophrenia. Recent studies suggest that CPLX4 modulates synaptic vesicle exocytosis and enhances the efficiency of synaptic transmission through its interaction with SNARE complexes. Understanding the structure-function relationship of recombinant CPLX4 can provide insights into its regulatory mechanisms and how alterations in its expression or function may lead to synaptic dysfunction. Additionally, investigating the role of CPLX4 in different types of neurons and its interaction with other synaptic proteins can illuminate its involvement in the maintenance of synaptic plasticity and overall brain function. This research not only contributes to our understanding of synaptic biology but also holds promise for identifying novel therapeutic targets for treating neurological disorders associated with synaptic abnormalities. Therefore, the recombinant expression and characterization of CPLX4 are essential for unraveling its biological significance and exploring its potential as a biomarker or therapeutic target in neurodevelopmental and neurodegenerative diseases.
